In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Discover the ESC Clinical Practice Guidelines on the topic

Arterial Hypertension

Current management of hypertension according to the new ESC Guidelines

ESC webinar

Add to calendar11/12/20140:00 11/12/20140:00 Europe/Paris Current management of hypertension according to the new ESC Guidelines European Society of Cardiology contact@escardio.org DD/MM/YYYY
Hypertension
Prevention
Chronic Nursing Care


Per Anton Sirnes and Antonio Coca

For the best learning experience, we recomment to read the ESC Guidelines on Arterial Hypertension (Management of)

 

 

The faculty will discuss the following issues:

  • To review the evidence and recommendations for silent organ damage evaluation in patients with hypertension
  • To discuss the usefulness of the “Table of total cardiovascular risk stratification” of the ESH/ESC 2013 Guidelines
  • To discuss and review the recommendations for the best antihypertensive therapeutic strategy in specific groups of patients at high risk

 

The ESC Webinars are designed to help you improve your daily practice!

The format includes a case based presentation, online assessment and live discussions with the 2 key opinion leaders who will give you some useful tips for your daily clinical practice.

 

Watch part one of the webinar

Watch part two of the webinar

Your questions answered by Professor Antonio Coca

Your questions answered by Dr Per Anton Sirnes

 

 

 

This programme is supported by Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo Europe GmbH, Novartis Pharma AG and SERVIER in the form of unrestricted educational grants.  The scientific programme has not been influenced in any way by its sponsors.